FRANKFURT – CureVac has recently shared encouraging results from its latest COVID-19 vaccine trials, conducted in collaboration with GSK. Preliminary data indicate that the vaccines, including a monovalent and a bivalent candidate, have generated strong immune responses even at lower doses and are well tolerated.
The monovalent vaccine candidate is designed to target the spike protein of the Omicron BA.4-5 variant, while the bivalent vaccine candidate targets the spike proteins of both the Omicron BA.4-5 variant and the SARS-CoV virus. -2 original. . These results mark an important step forward in ongoing efforts to develop effective vaccines against emerging COVID-19 variants.
As the company announces positive results from these trials, it is also preparing for discussions about advancing to a Phase 3 trial. This next phase is crucial to continue evaluating the efficacy and safety of vaccine candidates on a larger scale. Progression to Phase 3 will bring the vaccines one step closer to potential approval and public availability.
This article was generated with the support of AI and reviewed by an editor. For more information consult our T&C.
